# Cilostazol Dexborneol Versus Placebo for Microcirculation Dysfunction After Reperfusion Therapy in Patients With Acute Ischemic Stroke With Large Vessel Occlusion

Study · id `cardio:ct-nct05836766` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05836766](<https://clinicaltrials.gov/study/NCT05836766>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05836766

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT05836766. Randomized; quadruple masking; primary purpose treatment. Start 2023-06-05 (actual); primary completion 2024-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT05836766, source copy `cardio:ctgov-nct05836766-2023-09-28`, retrieved 2026-10-26)
- Started: 2023-06-05 (actual) (ClinicalTrials.gov record NCT05836766, source copy `cardio:ctgov-nct05836766-2023-09-28`, retrieved 2026-10-26)
- Primary completion: 2024-07 (anticipated) (ClinicalTrials.gov record NCT05836766, source copy `cardio:ctgov-nct05836766-2023-09-28`, retrieved 2026-10-26)
- Completion: 2024-08 (anticipated) (ClinicalTrials.gov record NCT05836766, source copy `cardio:ctgov-nct05836766-2023-09-28`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05836766, source copy `cardio:ctgov-nct05836766-2023-09-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05836766-2023-09-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Cilostazol Dexborneol Versus Placebo for Microcirculation Dysfunction After Reperfusion Therapy in Patients With Acute Ischemic Stroke With Large Vessel Occlusion
- Acronym: CRYSTAL
- Condition: Acute Ischemic Stroke
- Condition: Reperfusion
- Condition: Large Vessel Occlusion
- Intervention (Drug): Y-6 sublingual tablets
- Intervention (Drug): Placebo tablets of Y-6 sublingual tablet
- Lead sponsor: Beijing Tiantan Hospital
- Lead sponsor class: OTHER
- Collaborator: Neurodawn Pharmaceutical Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Beijing Tiantan Hospital (`cardio:org-beijing-tiantan-hospital`)
- Registry lists this organization as a collaborator: Neurodawn Pharmaceutical Co., Ltd. (`cardio:org-neurodawn-pharmaceutical-co-ltd`)

## Provenance

Content hash: 734e859f815e677c428c41a7013a8a52ee9ff1d5de2aa3c34bf383a5794e0fcf
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
